<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866279</url>
  </required_header>
  <id_info>
    <org_study_id>2016-6852</org_study_id>
    <nct_id>NCT02866279</nct_id>
  </id_info>
  <brief_title>Immediate Postpartum Contraceptive Implant Placement and Breastfeeding Success in Women at Risk for Low Milk Supply: A Non-inferiority Trial</brief_title>
  <official_title>Immediate Postpartum Contraceptive Implant Placement and Breastfeeding Success in Women at Risk for Low Milk Supply: A Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators goal is to measure the impact of timing of postpartum contraceptive implant&#xD;
      insertion on breastfeeding success and duration and to explore women's experiences with and&#xD;
      attitudes towards contraceptive and breastfeeding counseling in the peripartum time period&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immediate postpartum initiation of the etonogestrel contraceptive implant has been proven to&#xD;
      decrease rates of rapid, repeat pregnancies. Evidence supports that in healthy women with&#xD;
      term infants initiation of the contraceptive implant 1-3 days postpartum does not appear to&#xD;
      have any adverse effects on lactogenesis or breastfeeding continuation. However, no high&#xD;
      quality study to date has examined the effects of progestin-only contraception in women known&#xD;
      to be at risk for low milk supply, including women with a premature delivery, obesity,&#xD;
      polycystic ovarian syndrome, diabetes, or a prior history of low milk supply.&#xD;
&#xD;
      The investigators goal is to measure the impact of timing of postpartum contraceptive implant&#xD;
      insertion on breastfeeding success and duration. This will be a three-armed randomized&#xD;
      non-inferiority study of women who plan to breastfeed, have known risk factors for low milk&#xD;
      supply, and who intend to use the contraceptive implant postpartum. Women will be randomized&#xD;
      to one of three groups for the timing of contraceptive implant placement: within 30 minutes&#xD;
      of placental delivery, 24-72 hours postpartum, or 6 or more weeks postpartum. Women will be&#xD;
      assessed at 6 weeks, 3 months and 6 months postpartum. Outcomes will include time to&#xD;
      lactogenesis II, duration and exclusivity of breastfeeding, continuation of and satisfaction&#xD;
      with the contraceptive implant, and side effects, including bleeding patterns, associated&#xD;
      with the implant.&#xD;
&#xD;
      Findings from this trial will be used by clinicians, hospital systems, and policy makers&#xD;
      working to expand access to immediate postpartum implants while supporting women in meeting&#xD;
      their breastfeeding goals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Recruitment could not be completed&#xD;
  </why_stopped>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of breastfeeding</measure>
    <time_frame>6 months postpartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to lactogenesis II</measure>
    <time_frame>1-5 days postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal Bleeding</measure>
    <time_frame>0-6 months postpartum</time_frame>
    <description>Vaginal Bleeding will be assessed via a weekly questionnaire regarding total days of bleeding in the last week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with contraceptive implant</measure>
    <time_frame>0-6 months postpartum</time_frame>
    <description>Satisfaction will be assessed via a questionnaire at 6 weeks, 3 months, and 6 months postpartum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Contraception</condition>
  <condition>Breastfeeding</condition>
  <condition>Postpartum Contraception</condition>
  <arm_group>
    <arm_group_label>Postplacental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>contraceptive implant placed within 30 minutes of placental delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Postpartum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contraceptive Implant placed 1-3 days postpartum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contraceptive Implant placed 6 or more weeks postpartum</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etonogestrel Contraceptive Implant</intervention_name>
    <description>Women will be randomized to the TIMING of implant placement</description>
    <arm_group_label>Delayed</arm_group_label>
    <arm_group_label>Immediate Postpartum</arm_group_label>
    <arm_group_label>Postplacental</arm_group_label>
    <other_name>Nexplanon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Live pregnancy of at least 24 weeks gestation&#xD;
&#xD;
          -  Intention to use a contraceptive implant postpartum&#xD;
&#xD;
          -  17 years of age or older&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Admission to Labor and Delivery with a plan for delivery (women in both latent and&#xD;
             active labor will be eligible)&#xD;
&#xD;
          -  The presence of at least one of the following conditions known to be a risk factor for&#xD;
             low milk supply:&#xD;
&#xD;
               -  Expected delivery prior to 34 weeks&#xD;
&#xD;
               -  Obesity (pre-pregnancy BMI &gt;35)&#xD;
&#xD;
               -  Polycystic Ovarian Syndrome&#xD;
&#xD;
               -  Diabetes (gestational or pre-gestational)&#xD;
&#xD;
               -  Self-reported difficulty with low milk supply in past&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not English or Spanish speaking&#xD;
&#xD;
          -  Allergy or Contraindication to contraceptive implant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol. 2011 May;117(5):1114-1121. doi: 10.1097/AOG.0b013e3182165ee8.</citation>
    <PMID>21508750</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

